Aesther Healthcare (NASDAQ:AEHA) announced this morning that it has closed its combination with Ocean Biomedical after its shareholders approved the transaction at a special meeting on February 3.
The combined company’s shares and warrants are expected to begin trading today under the symbols “OCEA” and “OCEAW”, respectively.
Last week, Aesther announced it had secured a $60 million backstop agreement with Vellar Opportunity fund, adding to a common stock purchase agreement from White Lion Capital worth up to $75 million. Ocean Biomedical has also received $123.9 million in past and ongoing grants.
In the end, Aesther Healthcare shareholders tendered 98.9%, or 10,389,093, of its 10,500,000 public shares for redemption through votes, but the SPAC noted in an 8-K today that 3,365,515 public shares will remain as a 9.5% stake in the combined company likely thanks to the backstops.
Aesther Healthcare announced its $345 million combination with Ocean Biomedical on August 31, 2022. Providence, Rhode Island-based Ocean Biomedical is developing treatments for malaria and different cancer types.
It is the the second biotech combination to complete in 2023, following Orchestra Biomed’s (NASDAQ:OBIO) tie-up with Health Sciences 2 on January 27.
ADVISORS
- EF Hutton, division of Benchmark Investments, LLC, serves as capital markets advisor to Aesther Healthcare Acquisition Corp.
- Nelson Mullins Riley & Scarborough LLP serves as legal counsel to Aesther Healthcare Acquisition Corp.
- Malone Bailey, LLP serves as auditors to Aesther Healthcare Acquisition Corp.
- Dykema Gossett PLLC serves as legal counsel to Ocean Biomedical, Inc.
- Deloitte & Touche LLP serves as auditors to Ocean Biomedical, Inc.
At the SPAC of Dawn The Fed’s surprisingly aggressive decision to cut rates by 50 basis points yesterday gave a big boost to several SPACs and de-SPACs, many of which had endured a long slump while uncertainty over the coming interest rate climate reigned. None had a better day on paper than digital transformation firm...
Roman DBDR II (NASDAQ:DRDB) has filed for a $200 million SPAC with serial sponsor terms just as the team’s first deal undergoes a transition with other SPAC personalities. This new vehicle has its trust overfunded to 100.5% with $10.05 per share in trust out the gate. It also has 1/2 warrants in its units with...
At the SPAC of Dawn Christmas Day has finally arrived for SPAC watchers pining for a rate cut. The only question is how many basis point presents will they find under the tree when Fed Chair Jerome Powell takes the podium at 2 pm ET today. This is far from the only economic indicator set...
YHN Acquisition I Limited announced the pricing of its $60 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “YHNAU”, Wednesday, September 18, 2024. The new SPAC’s search will not be limited to a particular industry or geographic location, but the sponsors intend to target companies with a...
Chenghe II (NYSE:CHEB) has entered into a definitive agreement to combine with the Polibeli Group at a $3.6 billion equity value. Jakarta-based Polibeli operates an online and app-based wholesale marketplace for small businesses on Indonesia’s Java island. The combined company is expected to trade on the NYSE once the deal is completed. Transaction Overview Chenghe...